1. Home
  2. AVXL vs UCTT Comparison

AVXL vs UCTT Comparison

Compare AVXL & UCTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • UCTT
  • Stock Information
  • Founded
  • AVXL 2004
  • UCTT 1991
  • Country
  • AVXL United States
  • UCTT United States
  • Employees
  • AVXL N/A
  • UCTT N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • UCTT Semiconductors
  • Sector
  • AVXL Health Care
  • UCTT Technology
  • Exchange
  • AVXL Nasdaq
  • UCTT Nasdaq
  • Market Cap
  • AVXL 956.7M
  • UCTT 1.0B
  • IPO Year
  • AVXL N/A
  • UCTT 2004
  • Fundamental
  • Price
  • AVXL $9.95
  • UCTT $22.67
  • Analyst Decision
  • AVXL Strong Buy
  • UCTT Strong Buy
  • Analyst Count
  • AVXL 2
  • UCTT 3
  • Target Price
  • AVXL $44.00
  • UCTT $39.00
  • AVG Volume (30 Days)
  • AVXL 1.2M
  • UCTT 501.5K
  • Earning Date
  • AVXL 08-12-2025
  • UCTT 07-28-2025
  • Dividend Yield
  • AVXL N/A
  • UCTT N/A
  • EPS Growth
  • AVXL N/A
  • UCTT N/A
  • EPS
  • AVXL N/A
  • UCTT N/A
  • Revenue
  • AVXL N/A
  • UCTT $2,141,100,000.00
  • Revenue This Year
  • AVXL N/A
  • UCTT N/A
  • Revenue Next Year
  • AVXL N/A
  • UCTT $1.85
  • P/E Ratio
  • AVXL N/A
  • UCTT N/A
  • Revenue Growth
  • AVXL N/A
  • UCTT 14.28
  • 52 Week Low
  • AVXL $4.93
  • UCTT $16.66
  • 52 Week High
  • AVXL $14.44
  • UCTT $41.90
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 39.87
  • UCTT 46.55
  • Support Level
  • AVXL $9.90
  • UCTT $22.03
  • Resistance Level
  • AVXL $11.70
  • UCTT $24.54
  • Average True Range (ATR)
  • AVXL 0.70
  • UCTT 1.26
  • MACD
  • AVXL -0.23
  • UCTT -0.05
  • Stochastic Oscillator
  • AVXL 1.62
  • UCTT 22.10

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About UCTT Ultra Clean Holdings Inc.

Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.

Share on Social Networks: